Pharmaxis Ltd (AU:SNT) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Syntara Limited, an ASX-listed company, has attributed recent trading activity in its securities to investor anticipation of upcoming interim trial data on its SNT-5055 drug, as well as increased coverage by a major broker. The company plans to release the data after peer review at a scientific meeting and maintains that the information remains confidential. Despite market fluctuations, Syntara confirms its compliance with ASX listing rules.
For further insights into AU:SNT stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Bank of America Weighs in on Amazon Stock Amid AWS re:Invent 2024
- ‘Serious Drop Is in the Cards,’ Says Analyst About Palantir Stock
- Walmart’s (NYSE:WMT) $2.3 Billion Deal with Vizio Closes
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
